Azenta’s first quarter was marked by operational challenges and a more cautious demand environment, which contributed to results well below market expectations. CEO John Marotta acknowledged, “We are not satisfied with our second quarter results,” citing both internal execution gaps and continued customer spending constraints, especially in North America. Management attributed the revenue shortfall largely to softer demand across Multiomics, competitive pressures, and delays in capital equipment orders, with recurring revenue streams providing some stability. The company is now prioritizing operational discipline and organizational changes to address these issues.
Is now the time to buy AZTA? Find out in our full research report (it’s free for active Edge members).
Azenta (AZTA) Q1 CY2026 Highlights:
- Revenue: $144.8 million vs analyst estimates of $148.6 million (1% year-on-year growth, 2.5% miss)
- Adjusted EPS: -$0.04 vs analyst estimates of $0.14 (significant miss)
- Adjusted EBITDA: $7.78 million vs analyst estimates of $16.65 million (5.4% margin, 53.3% miss)
- Operating Margin: -114%, down from -12.7% in the same quarter last year
- Market Capitalization: $808 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Azenta’s Q1 Earnings Call
- David Saxon (Needham): Asked for detail on order cadence and conversion delays. CFO Lawrence Lin explained that major orders in automated storage and cryogenic systems were pushed out due to customer funding and site readiness, but the business was not lost, and biorepository growth remained strong.
- Matthew Stanton (Jefferies): Questioned the rationale for revising the long-range plan’s timing without lowering the financial targets. CEO John Marotta responded that while growth investments are being sustained, the delay reflects operational challenges in Multiomics, not a lack of conviction in the company’s strategic plan.
- Vijay Kumar (Evercore): Pressed management on whether weak North America results were market-driven or company-specific. Marotta attributed 60-70% of the Multiomics underperformance to Azenta’s own execution issues, particularly in the Sanger and GENEWIZ businesses, with the remainder due to broader market factors.
- Steven Etoch (Stephens): Sought clarification on the structural versus temporary nature of margin pressures in Multiomics. Lin indicated that overcapacity, especially in North American labs, is being addressed through restructuring and cost actions, with expected annualized savings from these efforts.
- Paul Knight (KeyBanc): Asked about quality improvements and the move to modular automated store systems. Marotta detailed the restructuring of engineering into specialized teams and a shift toward more modular, standardized products to improve reliability and reduce service issues.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will watch (1) whether the Multiomics transformation yields measurable improvements in North America volumes and margins, (2) the pace at which delayed capital equipment orders convert to revenue, and (3) continued momentum in recurring revenue businesses such as biorepositories and consumables. Developments in the integration of UK Biocentre and resolution of the B Medical transaction will also be critical signposts.
Azenta currently trades at $17.78, down from $24.61 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
